Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3b Study for Management of Ocular Side Effects in Subjects With EGFR-amplified Glioblastoma Receiving Depatuxizumab Mafodotin (ABT-414)

NCT03419403 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03419403
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03419403 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3b Study for Management of Ocular Side Effects in Subjects With EGFR-amplified Glioblastoma Receiving Depatuxizumab Mafodotin (ABT-414)
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Terminated
Start date
July 30, 2018
Completion date
March 3, 2020
Enrollment
40 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme